Coq10 for preventing cardiotoxicity in breast cancer patients treated with trastuzumab

Trastuzumab is a successful treatment option for HER2-positive breast cancer, but a decline in left ventricular ejection fraction (LVEF) and an increase in inflammatory and cardiac enzyme biomarkers can lead to cessation and termination of therapy. This study aimed to investigate the ability of Coen...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Hammadi, Nawal, AlSabri, Emad, Kudhair, Ahmed Hassan, Qassam, Heider, Hadi, Najah Rayish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652675/
https://www.ncbi.nlm.nih.gov/pubmed/38024827
http://dx.doi.org/10.25122/jml-2023-0098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652675/
https://www.ncbi.nlm.nih.gov/pubmed/38024827
http://dx.doi.org/10.25122/jml-2023-0098

Ejemplares similares